Disruption of p62 ubiquitination by α-methylene-γ-butyrolactone enhances Keap1 lysosomal degradation for ulcerative colitis therapy
Ke-Gang Linghu, Dasong Wang, Tian Zhang, Fei Jiang, Long Wu, Di Pan, Yan Chen, Ling Tao, Ligen Lin, Hua Yu, Qianming Du, Weidong Pan, Xiangchun Shen · 2026
Read Disruption of p62 ubiquitination by α-methylene-γ-butyrolactone enhances Keap1 lysosomal degradation for ulcerative colitis therapy by Ke-Gang Linghu, Dasong Wang, Tian Zhang, Fei Jiang, Long Wu, Di Pan, Yan Chen, Ling Tao, Ligen Lin, Hua Yu, Qianming Du, Weidong Pan, Xiangchun Shen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13675664.txt.
Description
Ke-Gang Linghu and co-authors tested a plant compound against gut inflammation in this 2026 study. The target illness is ulcerative colitis, a lasting inflammation of the colon. The compound is a small ring-shaped molecule found in anti-inflammatory herbs used in traditional medicine.
In mice, removing a guard protein called p62 made the disease worse. The compound latched onto p62 and shielded it from being tagged for disposal. That let p62 drag a second protein, Keap1, to the cell's recycling centers. Freeing a third protein then switched on the cell's antioxidant defenses. Gut inflammation eased, and immune cells calmed. Mutant mice lacking the latch point lost the benefit, which pins down how the drug works.
Catalog record
| CREATOR | Ke-Gang Linghu, Dasong Wang, Tian Zhang, Fei Jiang, Long Wu, Di Pan, Yan Chen, Ling Tao, Ligen Lin, Hua Yu, Qianming Du, Weidong Pan, Xiangchun Shen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |